Related Experiment Video
Updated: Sep 3, 2025
09:47
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
Published on: February 19, 2016
9.8K
Poly(lipoic acid)-based nanoparticles as a new therapeutic tool for delivering active molecules
Chiara Castellani1, Claudia Maria Radu2, Lucia Morillas-Becerril3
1Dept. of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Nanomedicine : Nanotechnology, Biology, and Medicine
|July 30, 2022
Summary
Pluronic-coated polylipoic acid-based nanoparticles (F127@PLA-NPs) show promising biodistribution and safety in rats. These nanoparticles effectively target organs like the heart and kidney, demonstrating their potential for drug delivery.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Pharmacology
Background:
- Biodegradable nanovectors are crucial for targeted drug delivery in complex diseases.
- Pluronic-coated polylipoic acid-based nanoparticles (F127@PLA-NPs) present potential as nanocarriers.
- Understanding in vivo behavior is essential for clinical translation.
Purpose of the Study:
- To evaluate the in vivo biodistribution and safety of F127@PLA-NPs in healthy rats.
- To assess the molecule delivery capability of F127@PLA-NPs.
- To investigate the potential of F127@PLA-NPs as a miRNA delivery system.
Main Methods:
- Intravenous administration of rhodamine B-labeled F127@PLA-NPs (10 mg/kg) in adult rats.
- Confocal microscopy analysis of NP fluorescence and MFI rate in collected organs.
- In vitro assessment of F127@PLA-NPs for miRNA delivery targeting cardiomyocytes.
Main Results:
- Maximal NP accumulation was observed in the heart compared to other organs.
- Myocytes and kidney tubular cells exhibited the highest NP uptake at the cellular level.
- No histopathological lesions or thrombogenicity were detected post-injection.
Conclusions:
- F127@PLA-NPs demonstrate favorable biodistribution, with preferential accumulation in the heart and kidney.
- The nanoparticles are safe for intravenous administration, showing no adverse effects.
- F127@PLA-NPs are effective in targeting specific cells, including cardiomyocytes, and show potential for miRNA delivery.
